Dr. Tabuteau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
45 Rockefeller Plaza Suite 1000
New York, NY 10111
Education & Training
Yale School of MedicineClass of 1994
Publications & Presentations
PubMed
- 61 citationsEffect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.Herriot Tabuteau, Amanda Jones, Ashley Anderson, Mark Jacobson, Dan V Iosifescu
The American Journal of Psychiatry. 2022-07-01 - 43 citationsEfficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).Dan V Iosifescu, Amanda Jones, Cedric O'Gorman, Caroline Streicher, Samantha Feliz
The Journal of Clinical Psychiatry. 2022-05-30 - 34 citationsRegional Distributions of Hippocampal Na+, K+-ATPase, Cytochrome Oxidase, and Total Protein in Temporal Lobe EpilepsyMichael L. Brines, H. Tabuteau, S. Sundaresan, Jung H. Kim, Dennis D. Spencer
Epilepsia. 1995-04-01
Press Mentions
Pharmanovia Enters in-Licensing Agreement with Axsome Therapeutics to Market and Further Develop Sunosi® (Solriamfetol), a First-in-Class Treatment for Excessive Daytime Sleepiness (EDS) in People with Narcolepsy and Obstructive Sleep ApnoeaFebruary 21st, 2023- Axsome Therapeutics (Finally) Earns Approval. Here's What's NextAugust 24th, 2022
- Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of PsychiatryMay 18th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
